Brokerages Set Immatics N.V. (NASDAQ:IMTX) Target Price at $14.67

Immatics N.V. (NASDAQ:IMTX - Get Free Report) has earned a consensus rating of "Buy" from the five research firms that are currently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $14.6667.

IMTX has been the subject of several research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immatics in a research report on Wednesday, May 28th. They issued a "buy" rating and a $10.00 price objective for the company. Wall Street Zen cut shares of Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. boosted its stake in Immatics by 38.4% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company's stock worth $66,194,000 after acquiring an additional 4,072,226 shares during the last quarter. Wellington Management Group LLP boosted its stake in Immatics by 7.6% during the 4th quarter. Wellington Management Group LLP now owns 10,417,892 shares of the company's stock worth $74,071,000 after acquiring an additional 736,709 shares during the last quarter. Baker BROS. Advisors LP boosted its stake in Immatics by 12.9% during the 4th quarter. Baker BROS. Advisors LP now owns 7,275,830 shares of the company's stock worth $51,731,000 after acquiring an additional 832,432 shares during the last quarter. Vestal Point Capital LP boosted its stake in Immatics by 14.6% during the 1st quarter. Vestal Point Capital LP now owns 7,192,700 shares of the company's stock worth $32,439,000 after acquiring an additional 917,700 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP boosted its stake in Immatics by 38.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 5,414,409 shares of the company's stock worth $38,496,000 after acquiring an additional 1,509,547 shares during the last quarter. Institutional investors own 64.41% of the company's stock.

Immatics Trading Up 3.7%

Shares of Immatics stock traded up $0.22 during mid-day trading on Monday, reaching $6.12. 63,819 shares of the stock were exchanged, compared to its average volume of 764,180. The company has a market cap of $743.89 million, a price-to-earnings ratio of -9.42 and a beta of 0.93. The firm has a 50-day simple moving average of $6.03 and a 200 day simple moving average of $5.19. Immatics has a fifty-two week low of $3.30 and a fifty-two week high of $13.09.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.28). The company had revenue of $6.48 million during the quarter, compared to analyst estimates of $13.05 million. Immatics had a negative net margin of 59.29% and a negative return on equity of 15.54%. On average, research analysts predict that Immatics will post -0.72 EPS for the current fiscal year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.